Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial

Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial

Abstract Background Steroid-resistant (SR) acute graft-versus-host disease (aGVHD) lacks standard second-line treatment. Mesenchymal stromal cells (MSCs) have potential efficacy in SR aGVHD. We aimed to assess the efficacy and safety of MSCs combined with basiliximab and calcineurin inhibitor as sec...

Full description

Bibliographic Details
Main Authors: Ke Zhao, Ren Lin, Zhiping Fan, Xiaoyong Chen, Yu Wang, Fen Huang, Na Xu, Xi Zhang, Xin Zhang, Li Xuan, Shunqing Wang, Dongjun Lin, Lan Deng, Danian Nie, Jianyu Weng, Yonghua Li, Xiaohui Zhang, Yuhua Li, A. P. Xiang, Qifa Liu
Format: Article
Language:English
Published: BMC 2022-03-01
Series:Journal of Hematology & Oncology
Subjects:
Mesenchymal stromal cell
Steroid-resistant acute graft-versus-host disease
Second-line treatment
Allogeneic hematopoietic stem cell transplantation
Online Access:https://doi.org/10.1186/s13045-022-01240-4

Internet

https://doi.org/10.1186/s13045-022-01240-4

Similar Items